STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
The FTC's move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers — and in particular, a practice known as bundling.
In an unexpected move, the Federal Trade Commission on Tuesday filed a lawsuit to block Amgen from acquiring Horizon Therapeutics, claiming the $27.8 billion deal would make it possible for Amgen to develop monopolies through a tactic that manipulates health coverage and drives up consumer costs.
At issue is a practice known as bundling. Simply put, a drug company combines two or more medicines in a package deal for health plans and pharmacy benefit managers, which determine lists of medicines that are covered by insurance. The practice has previously sparked concerns that a drug company will unfairly offer higher rebates for bundles in order to win favorable placement.
Such accusations have come up before. Notably, Regeneron Pharmaceuticals last year filed a lawsuit accusing Amgen of using a bundling scheme to entice health plans to cover a cholesterol medicine. Regeneron alleged Amgen relied on rebates for several medicines to win favorable formulary placement, and that the move effectively crowded out its own cholesterol drug.
What's Your Reaction?
